ReviewPharmaceutics2023
Ferrocene-Based Drugs, Delivery Nanomaterials and Fenton Mechanism: State of the Art, Recent Developments and Prospects.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Mapping the Landscape of Global Anticancer Organometallics Research: A Systematic Review.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025Pooled it
- Spatial Evolution of Antimicrobial Metallopolymers toward the Main Chain Topology.ACS central science · 2026Article
- Spiral Integration of Organic Synthesis and Instrumental Characterization Using Ferrocenyl Chalcones.Journal of chemical education · 2026Article
- Hybrid Aminoferrocenes With Nitrate Esters for In Situ Peroxynitrite Generation: Complex Interplay Between Redox Chemistry, NO-Donor Reactivity, and Aminoferrocene Activation Influences In Vitro Anticancer Activity.Chembiochem : a European journal of chemical biology · 2026Article
- Ferrocenoylation of Uracil Derivatives: Study of Reaction Regioselectivity and Biological Activity.Molecules (Basel, Switzerland) · 2026Article
- Benzimidazole-Quinoline Hybrids: Synthesis and Antimicrobial Properties.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Monodentate Transient Directing Group Enabled Distal C─H Bond Functionalization in Ferrocenecarboxaldehyde.Chemistry, an Asian journal · 2026Article
- NovelCancer drug resistance (Alhambra, Calif.) · 2026Article
- Curcumin and Resveratrol vs. Ferrocene-Modified Polyphenols: Role in Enhancing Protective Properties in Human Keratinocytes.Pharmaceutics · 2025Article
- Unraveling the structure-activity relationships of organometallic ferrocene-pyrazole and ferrocene-pyrimidine curcumin analogues in amyloid-β aggregation and glioblastoma treatment.Scientific reports · 2025Article
- Reaction of N-Ferrocenylcarbamates with Nitric Oxide: An Application for Detection of Inflammatory Sites In Vivo.ChemMedChem · 2025Article
- Design, Synthesis, and Biological Evaluation of Ferrocenyl-Cyclo-(Gly‑l‑Pro) Hybrids Sensitizing Multidrug-Resistant Cancer Cells to Anticancer Agents.ACS medicinal chemistry letters · 2025Article
- Host-Guest Complexes of Cyclopentadienyl Iron Dicarbonyl (CpFe(CO)Organometallics · 2025Article
- Organocyclophosphazenes and Materials Based on Them for Pharmaceuticals and Biomedicine.Biomolecules · 2025Review
- GSH/pH-responsive copper-based cascade nanocomplexes inducing immunogenic cell death through cuproptosis/ferroptosis/necroptosis in oral squamous cell carcinoma.Materials today. Bio · 2025Article
- Article
- Tumor microenvironment-responsive hyperbranched polymers for controlled drug delivery.Journal of pharmaceutical analysis · 2024Review
- Dendrimers, Dendrons, and the Dendritic State: Reflection on the Last Decade with Expected New Roles in Pharma, Medicine, and the Life Sciences.Pharmaceutics · 2024Review
- Programmable Release of Chemotherapeutics from Ferrocene-Based Injectable Hydrogels Slows Melanoma Growth.Advanced healthcare materials · 2024Article
- Recent Advances in the Field of Amino Acid-Conjugated Aminoferrocenes-A Personal Perspective.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Ferrocene has been the most used organometallic moiety introduced in organic and bioinorganic drugs to cure cancers and various other diseases. Following several pioneering studies, two real breakthroughs occurred in 1996 and 1997. In 1996, Jaouen et al. reported ferrocifens, ferrocene analogs of tamoxifen, the chemotherapeutic for hormone-dependent breast cancer. Several ferrocifens are now in preclinical evaluation. Independently, in 1997, ferroquine, an analog of the antimalarial drug chloroquine upon the introduction of a ferrocenyl substituent in the carbon chain, was reported by the Biot-Brocard group and found to be active against both chloroquine-sensitive and chloroquine-resistant strains of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.